HRP20000503B1 - A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE - Google Patents

A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE

Info

Publication number
HRP20000503B1
HRP20000503B1 HR20000503A HRP20000503A HRP20000503B1 HR P20000503 B1 HRP20000503 B1 HR P20000503B1 HR 20000503 A HR20000503 A HR 20000503A HR P20000503 A HRP20000503 A HR P20000503A HR P20000503 B1 HRP20000503 B1 HR P20000503B1
Authority
HR
Croatia
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
ethoxy
Prior art date
Application number
HR20000503A
Other languages
English (en)
Croatian (hr)
Inventor
Kay Bush Julie
Charles Conrad Preston
Gerard Flom Merlyn
Douglas Luke Wayne
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20000503A2 publication Critical patent/HRP20000503A2/hr
Publication of HRP20000503B1 publication Critical patent/HRP20000503B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20000503A 1999-07-29 2000-07-25 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE HRP20000503B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (2)

Publication Number Publication Date
HRP20000503A2 HRP20000503A2 (en) 2001-06-30
HRP20000503B1 true HRP20000503B1 (en) 2008-04-30

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000503A HRP20000503B1 (en) 1999-07-29 2000-07-25 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE

Country Status (45)

Country Link
EP (1) EP1204656A2 (xx)
JP (1) JP2001064277A (xx)
KR (1) KR100697177B1 (xx)
CN (1) CN1138770C (xx)
AR (1) AR031073A1 (xx)
AT (1) AT502318A1 (xx)
AU (1) AU6335600A (xx)
BE (1) BE1013411A3 (xx)
BR (1) BR0003209A (xx)
CA (1) CA2314682A1 (xx)
CO (1) CO5180570A1 (xx)
CZ (1) CZ299311B6 (xx)
DE (1) DE10036854A1 (xx)
DK (1) DK200001151A (xx)
DZ (1) DZ3060A1 (xx)
FI (1) FI20001722A (xx)
FR (1) FR2796944B1 (xx)
GB (1) GB2352717A (xx)
GR (1) GR1004084B (xx)
HK (1) HK1035370A1 (xx)
HR (1) HRP20000503B1 (xx)
HU (1) HUP0003001A2 (xx)
ID (1) ID27078A (xx)
IL (1) IL137553A (xx)
IT (1) IT1318660B1 (xx)
LT (1) LT4790B (xx)
LU (1) LU90617B1 (xx)
LV (1) LV12623B (xx)
MD (1) MD2336G2 (xx)
MX (1) MXPA00007461A (xx)
MY (1) MY128764A (xx)
NL (1) NL1015821C2 (xx)
NO (1) NO20003879L (xx)
PE (1) PE20010385A1 (xx)
PL (1) PL341749A1 (xx)
PT (1) PT102502A (xx)
RO (1) RO121851B1 (xx)
SE (1) SE0002792L (xx)
SG (1) SG91296A1 (xx)
SI (1) SI20426A (xx)
SV (1) SV2002000132A (xx)
TR (1) TR200002206A2 (xx)
TW (1) TWI276437B (xx)
UA (1) UA72885C2 (xx)
WO (1) WO2001009116A2 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208384T3 (es) * 1999-07-29 2004-06-16 Eli Lilly And Company Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
DZ3376A1 (fr) * 2000-05-08 2001-11-15 Lilly Co Eli Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
BR0114792A (pt) * 2000-10-20 2003-08-12 Lilly Co Eli Composto cristalino, anidro, não solvatado, de cloridreto de 6-hidróxi-3-(-4-[2-piperidin-1-il)-etóxi]-fenóxi)-2-(4-metóx i-fenil)-benzol[b]tiofeno (f-v), formulação farmacêutica, processo para preparar um composto, e uso de um composto
US6921827B2 (en) 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
ES2349798T3 (es) * 2004-07-22 2011-01-11 Eli Lilly And Company Hidrato variable cristalino de la sal hemisuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2-hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinocarboxamida.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44597A1 (es) * 1995-02-28 1997-10-13 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Also Published As

Publication number Publication date
MD20000162A (en) 2001-04-30
SE0002792D0 (sv) 2000-07-28
GB0018641D0 (en) 2000-09-13
HK1035370A1 (en) 2001-11-23
FR2796944A1 (fr) 2001-02-02
CN1288007A (zh) 2001-03-21
MD2336F2 (en) 2003-12-31
CA2314682A1 (en) 2001-01-29
MXPA00007461A (es) 2004-07-16
HUP0003001A2 (hu) 2002-04-29
NL1015821C2 (nl) 2002-01-03
LV12623B (en) 2001-07-20
AR031073A1 (es) 2003-09-10
WO2001009116A2 (en) 2001-02-08
ITMI20001759A0 (it) 2000-07-28
BE1013411A3 (fr) 2001-12-04
AU6335600A (en) 2001-02-19
IL137553A0 (en) 2001-07-24
SI20426A (sl) 2001-06-30
BR0003209A (pt) 2001-03-20
TR200002206A2 (tr) 2001-03-21
CO5180570A1 (es) 2002-07-30
MD2336G2 (ro) 2004-06-30
IT1318660B1 (it) 2003-08-27
CN1138770C (zh) 2004-02-18
PT102502A (pt) 2001-01-31
DE10036854A1 (de) 2001-03-01
FI20001722A0 (fi) 2000-07-28
NO20003879L (no) 2001-01-30
HRP20000503A2 (en) 2001-06-30
ITMI20001759A1 (it) 2002-01-28
LV12623A (en) 2001-03-20
AT502318A1 (de) 2007-02-15
KR20010049916A (ko) 2001-06-15
FI20001722A (fi) 2001-01-30
JP2001064277A (ja) 2001-03-13
GB2352717A (en) 2001-02-07
IL137553A (en) 2005-09-25
SE0002792L (sv) 2001-01-30
KR100697177B1 (ko) 2007-03-21
LU90617B1 (fr) 2001-06-15
SG91296A1 (en) 2002-09-17
LT2000076A (lt) 2001-02-26
GR20000100265A (el) 2001-03-30
ID27078A (id) 2001-02-22
NL1015821A1 (nl) 2001-01-30
IE20000605A1 (en) 2001-04-04
LT4790B (lt) 2001-05-25
FR2796944B1 (fr) 2003-01-31
DK200001151A (da) 2001-01-30
UA72885C2 (uk) 2005-05-16
SV2002000132A (es) 2002-06-07
CZ20002716A3 (en) 2001-05-16
MY128764A (en) 2007-02-28
CZ299311B6 (cs) 2008-06-18
PE20010385A1 (es) 2001-04-06
PL341749A1 (en) 2001-02-12
NO20003879D0 (no) 2000-07-28
WO2001009116A3 (en) 2001-05-17
TWI276437B (en) 2007-03-21
HU0003001D0 (en) 2000-10-28
DZ3060A1 (fr) 2004-05-22
GR1004084B (el) 2002-12-11
EP1204656A2 (en) 2002-05-15
RO121851B1 (ro) 2008-06-30

Similar Documents

Publication Publication Date Title
DE60038481D1 (de) Kristalline form des (r)-2-äää3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinylümethylüsulfinylü-1h-benzimidazols
RS49870B (sr) Polimorfni oblik klopidogrel vodonik sulfata
HUP0204034A3 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
HRP20000502B1 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE
HRP20000503B1 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-/2-(PIPERIDIN-1-YL)ETHOXY/PHENOXY)-2-(4-METHOXYPHENYL)BENZO/b/THIOPHENE HYDROCHLORIDE
HK1068611A1 (en) New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias
MXPA02002838A (es) Derivados de piperazina sustituidos, su obtencion y uso como medicamentos.
MXPA03003432A (es) Nueva forma cristalina de clorhidrato de 6-hidroxi -3-(4 -(2 -(piperidin-1- il)etoxi)fenoxi) -2-(4-metoxifenil) benzo (b) tiofeno.
BG105011A (en) Composition containing paroxetine
CY2344B1 (en) A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
TJ398B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.
TJ399B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ- phenoxy) -2-(4-methoxyphenyl) benzo ÄBÜ thiophene hydrochloride.
ZA200003838B (en) A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
ECSP003592A (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6- HIDROXI- 3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO [b]TIOFENO
ECSP003593A (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6- HIDROXI- 3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO [b]TIOFENO
HUP0001928A2 (en) Process for preparing 2-phenyl-3-aminopyridine, substituted phenyl derivatives thereof and salts thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080707

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20090726